- Home
- BRT vs AQST Comparison
BRT vs AQST Comparison
Compare BRT & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BRT | AQST |
|---|---|---|
| Founded | 1972 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 271.2M | 529.4M |
| IPO Year | 1994 | 2007 |
Fundamental Metrics
Financial Performance| Metric | BRT | AQST |
|---|---|---|
| Price | $14.19 | $5.24 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $19.75 | $9.00 |
| AVG Volume (30 Days) | 29.9K | ★ 3.8M |
| Earning Date | 05-08-2026 | 05-01-2026 |
| Dividend Yield | ★ 7.03% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $97,028,000.00 | $67,430,000.00 |
| Revenue This Year | $3.82 | $10.08 |
| Revenue Next Year | $5.35 | $49.60 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1.46 | 0.77 |
| 52 Week Low | $13.18 | $2.94 |
| 52 Week High | $16.69 | $7.55 |
Technical Indicators
Market Signals| Indicator | BRT | AQST |
|---|---|---|
| Relative Strength Index (RSI) | 42.87 | 66.47 |
| Support Level | $14.19 | $3.70 |
| Resistance Level | $14.94 | $5.41 |
| Average True Range (ATR) | 0.31 | 0.26 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 0.00 | 85.11 |
Price Performance
Historical ComparisonAbout BRT BRT Apartments Corp. (MD)
BRT Apartments Corp is a real estate investment trust company. The company is focused on the ownership, operation, and development of multi-family properties. BRT also owns and operates other real estate assets. All of the Company's assets are comprised of multi-family real estate assets generally leased to tenants on a one-year basis.
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.